Gowns intended for use in healthcare settings must adequately provide a liquid barrier. This draft guidance provides FDA’s current thinking on the regulatory requirements and performance testing needed to support liquid barrier claims for gowns. Gowns can make two claims to barrier protection Minimal or Low Barrier protection: a. ANSI/AAMI PB70 Level 1 protection
FDA released this draft guidance to provide its current thinking on direct marking of devices in regards to UDI requirements. For devices that are intended to be used more than once and reprocessed before each use, they must bear a UDI on the device itself if it is also are required to have a UDI
FDA requires an IDE prior to a sponsor initiating a clinical investigation for devices which FDA has determined to be Significant Risk. Through the IDE, the sponsor must demonstrate how the risks to the subjects are not outweighed by the anticipated benefits. If FDA is unable to determine that the benefits to the patients are
New FDA Update!!! Over the next two years FDA may require all new drug and biologic submissions to be sent electronically. FDA will adhere to the International Conference on Harmonization’s (ICH) electronic common technical document (eCTD) format. Adoption of this format will allow companies to submit an application for a new pharmaceutical or biological product
On April 20th of this year two senators from Maine and California introduced the Personal Care Products Safety Act . If passed, this bill would expand FDA’s authority over cosmetic products sold in the United States. The changes are similar to that of requirements for nonprescription drugs including cosmetic GMP’s and ingredient review, establishment and
FDA draft guidance released There are many reasons why a sponsor may want to conduct a clinical trial Outside of the United States (OUS). Question is, will FDA accept this data to support marketing the device in the U.S.? Short answer, yes – provided certain conditions are met. For a PMA, under 21 CFR 814.15(b),
PILOT PROGRAM FDA is accepting requests starting May 1st to May 31st 2015 for participation in their pilot program for electronic submission of home use device labeling. The labelling, including safety information and instructions for use, will be submitted through the registration and listing database. This database will be available to patients, caregivers, and the
As part of the EAP program, FDA intends to provide more interactive communications during device development and more interactive review of Investigational Device Exemption applications, PMA applications, and requests for de novo review. This includes working with the sponsor to create a data development plan specific to the device, which would outline all data the
We have been recently getting a lot of queries whether or not FDA can still issue NDC/NHRIC labeler codes for medical devices with the recent advent of the new UDI (Unique Device Identification) regulations being implemented by the FDA. The answer to this question is NO!!! Some of the clients are arguing about the NDC
Clients, please be aware of the final release of the guidance document for reprocessing of medical devices. Earlier this month news came out of a fatal bacterial infection at UCLA Medical Center. The infection was spread by an endoscope, a type of reusable medical device. This sparked discussion around the topic of what role the
mdi Consultants